Advances in Personalized Medicine and Non ‐Invasive Diagnostics in Solid Organ Transplantation

AbstractPersonalized medicine has been a mainstay and in practice in transplant pharmacotherapy since the advent of the field. Decisions pertaining to the diagnosis, selection, and monitoring of transplant pharmacotherapy are aimed toward the individual, the allograft, and the overall immunologic needs of the patient. Recent advances in pharmacogenomics, non ‐invasive biomarkers and artificial intelligence technologies have the promise of transforming the way we individualize treatment and monitor allograft function. Pharmacogenomic testing can provide clinicians with additional data that can minimize toxicity and maximize therapeutic dosing in high r isk patients, leading to more informed decisions that may decrease the risk of rejection and adverse outcomes related to immunosuppressive therapies. Development of non‐invasive strategies to monitor allograft function may offer safer and more convenient methods to detect allograft injury. Cell fr ee DNA and gene expression profiling offer the potential to serve as “liquid biopsies” minimizing risk to patients and providing clinicians with useful molecular data that may help individualize immunosuppression and rejection treatment. Use of big data in transplant and novel artificial intelli gence platforms, such as the iBox, hold tremendous promise in providing clinicians a “glimpse into the future” thereby allowing for a more individualized approach to immunosuppressive therapy that may minimize future adverse outcome...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: TI ON TRANSPLANTATION Source Type: research